Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBPNASDAQ:IMNMNYSE:PRMENASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$19.36+0.6%$19.25$15.47▼$36.37$662.36M1.47177,573 shs136,991 shsIMNMImmunome$8.06+0.8%$7.65$5.15▼$16.81$701.32M2921,008 shs1.13 million shsPRMEPrime Medicine$1.59+26.2%$1.57$1.12▼$8.27$208.76M1.91.25 million shs2.63 million shsTRVITrevi Therapeutics$6.50+5.0%$6.29$2.30▼$7.39$649.30M0.621.19 million shs1.65 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma0.00%-3.05%+6.73%-27.22%-0.72%IMNMImmunome0.00%+8.04%+1.90%-22.50%-45.54%PRMEPrime Medicine0.00%+22.31%+28.23%-44.01%-76.48%TRVITrevi Therapeutics0.00%-1.52%+7.08%+59.71%+135.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVBPArriVent BioPharma1.027 of 5 stars3.60.00.00.02.00.00.0IMNMImmunome2.6546 of 5 stars4.50.00.00.03.22.50.0PRMEPrime Medicine2.8189 of 5 stars3.60.00.00.02.53.30.6TRVITrevi Therapeutics3.4623 of 5 stars4.72.00.00.03.13.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 3.17Buy$39.17102.31% UpsideIMNMImmunome 3.00Buy$23.33189.50% UpsidePRMEPrime Medicine 3.17Buy$13.40742.77% UpsideTRVITrevi Therapeutics 3.30Buy$17.56170.19% UpsideCurrent Analyst Ratings BreakdownLatest PRME, IMNM, AVBP, and TRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.004/8/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/2/2025IMNMImmunomeLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/20/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.003/20/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.003/20/2025IMNMImmunomeStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.003/20/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $25.003/20/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/19/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/19/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A($4.79) per shareN/AIMNMImmunome$9.04M77.57N/AN/A$2.77 per share2.91PRMEPrime Medicine$3.85M54.28N/AN/A$1.37 per share1.16TRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$69.33M-$3.77N/AN/AN/AN/A-43.89%-29.67%N/AIMNMImmunome-$106.81M-$3.18N/AN/AN/A-3,014.59%-48.63%-41.62%N/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ATRVITrevi Therapeutics-$29.07M-$0.45N/AN/AN/AN/A-63.31%-57.06%N/ALatest PRME, IMNM, AVBP, and TRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AVBPArriVent BioPharma-$0.66-$1.90-$1.24-$1.90N/AN/A5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/6/2025Q1 2025TRVITrevi Therapeutics-$0.13-$0.09+$0.04-$0.09N/AN/A3/19/2025Q4 2024IMNMImmunome-$0.68-$0.84-$0.16-$1.28$3.07 million$2.74 million3/18/2025Q4 2024TRVITrevi Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/A3/7/2025Full YearPRMEPrime MedicineN/A-$1.65N/AN/AN/AN/A3/3/2025Q4 2024AVBPArriVent BioPharma-$0.78-$0.60+$0.18-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/APRMEPrime Medicine$1.4590.94%N/AN/A N/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A19.2819.28IMNMImmunomeN/A6.176.17PRMEPrime MedicineN/A6.506.50TRVITrevi TherapeuticsN/A7.387.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%IMNMImmunome44.58%PRMEPrime Medicine70.37%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharmaN/AIMNMImmunome8.60%PRMEPrime Medicine23.47%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4034.21 millionN/AN/AIMNMImmunome4087.01 million72.92 millionOptionablePRMEPrime Medicine234131.29 million100.38 millionOptionableTRVITrevi Therapeutics2099.89 million58.13 millionOptionablePRME, IMNM, AVBP, and TRVI HeadlinesRecent News About These CompaniesTrevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Holdings Increased by MPM Bioimpact LLCMay 16 at 8:38 AM | marketbeat.comWall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?May 14, 2025 | zacks.comTrevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comBarclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 10, 2025 | marketbeat.comTrevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finanznachrichten.deTrevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finance.yahoo.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from AnalystsMay 9, 2025 | marketbeat.comMarshall Wace LLP Sells 38,203 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 8, 2025 | marketbeat.comAlly Bridge Group NY LLC Lowers Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 4, 2025 | marketbeat.comAcuta Capital Partners LLC Has $3.18 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 4, 2025 | marketbeat.comAcorn Capital Advisors LLC Invests $8.24 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 4, 2025 | marketbeat.comBoothbay Fund Management LLC Takes $387,000 Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 4, 2025 | marketbeat.comTrevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025May 1, 2025 | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Here's WhyMay 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Takes Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)April 30, 2025 | marketbeat.comJPMorgan Chase & Co. Boosts Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)April 30, 2025 | marketbeat.comXTX Topco Ltd Makes New Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)April 28, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Silverarc Capital Management LLCApril 24, 2025 | marketbeat.comVivo Capital LLC Boosts Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)April 23, 2025 | marketbeat.comTrevi Therapeutics management to meet virtually with B. RileyApril 22, 2025 | markets.businessinsider.comTrevi Therapeutics management to meet with Cantor FitzgeraldApril 11, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRME, IMNM, AVBP, and TRVI Company DescriptionsArriVent BioPharma NASDAQ:AVBP$19.36 +0.12 (+0.62%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$19.37 +0.01 (+0.05%) As of 05/16/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Immunome NASDAQ:IMNM$8.06 +0.06 (+0.75%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$7.99 -0.07 (-0.87%) As of 05/16/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Prime Medicine NYSE:PRME$1.59 +0.33 (+26.19%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.72 +0.13 (+7.86%) As of 05/16/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Trevi Therapeutics NASDAQ:TRVI$6.50 +0.31 (+5.01%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$6.56 +0.06 (+0.86%) As of 05/16/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
